Stable and soluble antibodies
US10570198B2 · kind B2 · utility
2Cited by
51References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 18, 2016 |
| Grant date | Feb 25, 2020 |
| Priority date | — |
| Expiry date | Sep 22, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.